EUVIMEDDescubrir EUVIMED
Open access · CC BY-NC-ND 4.0

Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis

Lucía Pascual-Antón iD, Pilar Sandoval iD, Guadalupe T González-Mateo, Valeria Kopytina, Henar Tomero-Sanz, Eva María Arriero-País, José Antonio Jiménez-Heffernan, Myriam Fabre, Isabel Egaña, Cristina Ferrer, Laureano Simón, Lucía González-Cortijo and 2 more

The Journal of Pathology · 2023

DOI: 10.1002/path.6170 ↗

At a glance

Journal article in The Journal of Pathology, 2023. Written by Lucía Pascual-Antón and 13 co-authors. Institution: Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa - Consejo Superior de Investigaciones Científicas - Universidad Autón…. Major MEDLINE topics: Peritoneal Neoplasms, Immunoconjugates, Carcinoma, Ovarian Neoplasms. Cited 15 times so far (Crossref); 69 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Ministerio de Ciencia e Innovación.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Ovarian carcinomatosis is characterized by the accumulation of carcinoma‐associated mesothelial cells (CAMs) in the peritoneal stroma and mainly originates through a mesothelial‐to‐mesenchymal transition (MMT) process. MMT has been proposed as a therapeutic target for peritoneal metastasis. Most ovarian cancer (OC) patients present at diagnosis with peritoneal seeding, which makes tumor progression control difficult by MMT modulation. An alternative approach is to use antibody–drug conjugates (ADCs) targeted directly to attack CAMs. This strategy could represent the cornerstone of precision‐based medicine for peritoneal carcinomatosis. Here, we performed complete transcriptome analyses of ascitic fluid‐isolated CAMs in advanced OC patients with primary‐, high‐, and low‐grade, serous subtypes and following neoadjuvant chemotherapy. Our findings suggest that both cancer biological aggressiveness and chemotherapy‐induced tumor mass reduction reflect the MMT‐associated changes that take place in the tumor surrounding microenvironment. Accordingly, MMT‐related genes, including fibroblast activation protein ( FAP ), mannose receptor C type 2 ( MRC2 ), interleukin‐11 receptor alpha ( IL11RA ), myristoylated alanine‐rich C‐kinase substrate ( MARCKS ), and sulfatase‐1 ( SULF1 ), were identified as specific actionable targets in CAMs of OC patients, which is a crucial step in the de novo design of ADCs. These cell surface target receptors were also validated in peritoneal CAMs of colorectal cancer peritoneal implants, indicating that ADC‐based treatment could extend to other abdominal tumors that show peritoneal colonization. As proof of concept, a FAP‐targeted ADC reduced tumor growth in an OC xenograft mouse model with peritoneal metastasis‐associated fibroblasts. In summary, we propose MMT as a potential source of ADC‐based therapeutic targets for peritoneal carcinomatosis. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Peritoneal NeoplasmsImmunoconjugatesCarcinomaOvarian NeoplasmsFemaleHumansMiceAnimalsPeritoneumFibroblastsDisease Models, AnimalCell Line, TumorTumor Microenvironment

Author keywords

antibody-drug conjugatescarcinoma-associated mesothelial cellsmesothelial-to-mesenchymal transitionovarian cancerperitoneal carcinomatosis

Substances

Immunoconjugates

Authors and institutions

  • Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa - Consejo Superior de Investigaciones Científicas - Universidad Autónoma de Madrid (CBMSO-CSIC-UAM), Madrid, Spain.
  • Department of Pathology, Hospital Universitario de la Princesa, Madrid, Spain.
  • Oncomatryx Biopharma, Vizcaya, Spain.
  • Hospital Universitario QuirónSalud Madrid, Madrid, Spain.

ORCID profiles: Lucía Pascual-Antón, Pilar Sandoval

Funding

  • Ministerio de Ciencia e Innovación

Cite

APA

Pascual-Antón, L., Sandoval, P., González-Mateo, G. T., Kopytina, V., Tomero-Sanz, H., Arriero-País, E. M., Jiménez-Heffernan, J. A., Fabre, M., Egaña, I., Ferrer, C., Simón, L., González-Cortijo, L., Sainz de la Cuesta, R., & López-Cabrera, M. (2023). Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis. The Journal of Pathology. https://doi.org/10.1002/path.6170

Vancouver

Pascual-Antón L, Sandoval P, González-Mateo GT, Kopytina V, Tomero-Sanz H, Arriero-País EM, et al. Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis. The Journal of Pathology. 2023. doi:10.1002/path.6170

BibTeX
@article{PascualAntn2023,
  author = {Pascual-Antón, Lucía and Sandoval, Pilar and González-Mateo, Guadalupe T and Kopytina, Valeria and Tomero-Sanz, Henar and Arriero-País, Eva María and Jiménez-Heffernan, José Antonio and Fabre, Myriam and Egaña, Isabel and Ferrer, Cristina and Simón, Laureano and González-Cortijo, Lucía and Sainz de la Cuesta, Ricardo and López-Cabrera, Manuel},
  title = {Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6170}
}
Start for free →